Why Doughnut Maker Krispy Kreme Shares Are Falling Today

Krispy Kreme shares dip premarket as Q4 earnings miss analyst estimates despite solid sales growth; outlook disappoints.

Krispy Kreme, Inc. (NASDAQ:DNUT) shares are trading lower in the premarket session on Tuesday.

The company reported fourth-quarter FY23 sales growth of 11.4% year over year to $450.9 million, beating the analyst consensus estimate of $438.94 million.

The company reported adjusted diluted EPS of $0.09, missing the analyst consensus of $0.13. 

Earnings were affected by increased depreciation and amortization as the company expanded the availability of doughnuts and Insomnia Cookies globally, Krispy Kreme said in a press release.

On October 3, 2023, the company announced it is exploring strategic alternatives for Insomnia Cookies. 

The company’s total organic revenue grew 13.2%, driven by high-impact global brand activations and seasonal offerings, increased points of access, and premiumization efforts. 

In the U.S. segment, net revenue grew 9.3%, with organic revenue growth of 13.7%. In the International segment, net revenue grew 15.2%, with organic revenue growth of 9%.

In the Market Development segment, net revenue grew 17.2%, and organic growth in the segment was 19.2%.

E-commerce as a percentage of retail sales increased 130 basis points to 19.3% of sales.

Adjusted EBITDA increased 14.7% to $64.1 million, while adjusted EBITDA margins improved 40 basis points to 14.2%.

As of December 31, 2023, the company has a total available liquidity of $197.2 million, including $38.2 million of cash and cash equivalents.

Outlook: Krispy Kreme expects FY24 adjusted diluted EPS of $0.27-$0.31 versus the $0.38 estimate. 

The company projects FY24 net revenue growth of 5%-7% and adjusted EBITDA growth of 8%-11%. 

Guidance for the full year 2024 includes operations from Insomnia Cookies.

Price Action: DNUT shares are trading lower by 3.83% to $13.30 premarket on the last check Tuesday. 

Photo via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

Wiley Announces CEO Transition; Brian Napack To Depart The Company As President And CEO Effective Immediately; Matthew Kissner, Appointed Interim CEO; Wiley To Reschedule Its Planned October 12 Investor Day For A Later Date To Be Determined

Brian Napack to depart the Company as President and CEO effective immediatelyFormer Group Executive and Board Chair, Matthew Kissner, appointed Interim CEOWiley to reschedule its planned October 12 Investor Day for a

WLY

Read More

Watching Bausch Health Companies; Seeking Alpha Reports, Court Ruling In Patent Dispute With Norwich Pharma; Court Issued An Order Denying Norwich’s Motion To Modify Judgment In The Case Of: “Salix Pharmaceuticals, Ltd. Norwich Pharmaceuticals, Inc.”

https://seekingalpha.com/news/3972676-bausch-health-soars-after-court-ruling-in-patent-dispute-with-norwich-pharma?utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated Bausch Health (NYSE:BHC) soared 40% after a court ruling related to the company’s patent suit vs Norwich Pharma over…

BHC